Adaptive Biotechnologies Corporation Common Stock
Here’s whether Adaptive Biotechnologies Corporation Common Stock (ADPT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.67% over 10 days); strong 1-year return of +69.1%; 3-month momentum positive (+32.1%); rising volume confirms the move (1.28x 30d avg). Currently 15.2% off its 52-week high. Score: +7/7.
ADPT is in a confirmed uptrend, trading above both its 50-day ($14.57) and 200-day ($15.38) moving averages. An RSI of 68.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +69.1% compares to +22.9% for SPY (beat the market by 46.2%).